Effects of dialkoxylphenyl compounds with oxime group on macrophage function and the proliferation of lymphocytes

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 4, 2004, Pages 503-512

  Yoo, Eun Sook ^a,b   Son, Ho Jung ^b   Park, Joon Seok ^b   Kim, Ae Ra ^b   Baik, Kyong Up ^b   Park, Myung Hwan ^b   Cho, Jae Youl ^b,c  

^a Jeju National University School of Medicine   (South Korea)

^b Daewoong Pharmaceutical Co Ltd   (South Korea)

^c Kangwon National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL) 3 OXO 2,3 DIHYDRO 1H ISOINDOLE 5 CARBALDEHYDE OXIME; 2 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL) 6 (2 [1,3]DIOXOLAN 2 YL VINYL) 2,3 DIHYDRO ISOINDOL 1 ONE; 3 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL)PROPENALOXIME; 3 (3,4,5 TRIMETHOXYPHENYL)PROPENALOXIME; 3 (4,5 TRIMETHOXYPHENYL)PROPENALOXIME; 6 (2 (3 CYCLOPENTYLOXY 4 METHOXYPHENYL)VINYL)PYRIDINE 2 CARBALDEHYDE OXIME; ALKOXYBENZENE DERIVATIVE; ANTIINFLAMMATORY AGENT; AUTACOID; CONCANAVALIN A; CYCLIC AMP DEPENDENT PROTEIN KINASE; DRUG METABOLITE; ENZYME ACTIVATOR; FUNCTIONAL GROUP; HERBIMYCIN A; INTERLEUKIN 2; LEFLUNOMIDE; LIPOPOLYSACCHARIDE; NITRIC OXIDE; OXIME; OXIME DERIVATIVE; PHENYL GROUP; PHOSPHODIESTERASE IV; PHOSPHODIESTERASE IV INHIBITOR; PREDNISOLONE; ROLIPRAM; STAUROSPORINE; TERIFLUNOMIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANALYTIC METHOD; ANIMAL CELL; ANIMAL EXPERIMENT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BINDING SITE; BIOSYNTHESIS; CELL ACTIVATION; CELL STIMULATION; CELL STRAIN; CONTROLLED STUDY; DOSE RESPONSE; DRUG COMPETITION; DRUG POTENCY; DRUG POTENTIATION; DRUG RESEARCH; DRUG SCREENING; DRUG SYNTHESIS; ENZYME STRUCTURE; GEOMETRY; HYDROGEN BOND; IN VITRO STUDY; IN VIVO STUDY; LYMPHOCYTE PROLIFERATION; MACROPHAGE ACTIVATION; MACROPHAGE FUNCTION; MOLECULAR INTERACTION; MOLECULAR SIZE; MOUSE; NONHUMAN; PROTEIN SECRETION; STATISTICAL SIGNIFICANCE; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADJUVANTS, IMMUNOLOGIC; ANIMALS; CELL DIVISION; DOSE-RESPONSE RELATIONSHIP, DRUG; MACROPHAGES; MALE; MICE; MICE, INBRED BALB C; NITRIC OXIDE; OXIMES; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1842471921     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357023042     Document Type: Article

References (44)

1. Baik, K. U., Yoo, E. S., Byun, Y., Lee, S. J., Jang, B., Son, H. J., Lee, J. H., Cho, J. Y., Lee, S., Moon, S., Park, J., Lee, B. (1998) Novel 3,4-dialkoxyphenylderivatives and their therapeutic use thereof. Patent: WO9842666
2. Barnette, M. S. (1999) Phosphodiesterase 4 (PDE4) inhibitors in asthma and chronic obstructive pulmonary disease (COPD). Prog. Drug Res. 53: 193-229
3. Baures, P. W., Eggleston, D. S., Erhard, K. F., Cieslinski, L. B., Torphy, T. J., Christensen, S. B. (1993) The crystal structure, absolute configuration, and phosphodiesterase inhibitory activity of (+)-1-(4-bromobenzyl)-4-(3-(cyclopentyloxy)- 4-methoxyphenyl)-pyrrolidin-2-one. J. Med. Chem. 36: 3274-3277
4. Beavo, J. A., Conti, M., Heaslip, R. J. (1994) Multiple cyclic nucleotide phosphodiesterases. Mol. Pharmacol. 46: 399-405
5. Beutler, B. (1995) TNF, immunity and inflammatory disease: lessons of the past decade. J. Invest. Med. 43: 227-235
6. Brackeen, M. F., Cowan, D. J., Stafford, J. A., Schoenen, F. J., Veal, J. M., Domanico, P. L., Rose, D., Strickland, A. B., Verghese, M., Feldman, P. L. (1995) Design and synthesis of conformationally constrained analogues of 4-(3-butoxy-4 -methoxybenzyl)imidazolidin-2-one (Ro 20-1724) as potent inhibitors of cAMP-specific phosphodiesterase. J. Med. Chem. 38: 4848-4854
7. Cho, J. Y., Yoo, E. S., Baik, K. U., Park, M. H. (1999a) Eudesmin inhibits tumor necrosis factor-alpha production and T cell proliferation. Arch. Pharm. Res. 22: 348-353
8. Cho, J. Y., Kim, A. R., Yoo, E. S., Baik, K. U., Park, M. H. (1999b) Immunomodulatory effect of arctigenin on tumor necrosis factor-α and nitric oxide production, and lymphocyte proliferation. J. Pharm. Pharmacol. 51: 1267-1273
9. Cho, J. Y., Baik, K. U., Jung, J. H., Park, M. H. (2000a) In vitro anti-inflammatory effects of cynaropicrin, a sesquiterpene lactone, from Saussurea lappa. Eur. J. Pharmacol. 398: 399-407
10. Cho, J. Y., Baik, K. U., Yoo, E. S., Yoshikawa, K., Park, M. H. (2000b) In vitro antiinflammatory effects of neolignan woorenosides from the rhizomes of Coptis japonica. J. Nat. Prod. 63: 1205-1209
11. Cho, J. Y., Yoo, E. S., Baik, K. U., Park, M. H., Han, B. H. (2001) In vitro inhibitory effect of protopanaxadiol ginsenosides on tumor necrosis factor (TNF)-alpha production and its modulation by known TNF-alpha antagonists. Planta Med. 67: 213-218
12. Correll, P. H., Iwama, A., Tondat, S., Mayrhofer, G., Suda, T., Bernstein, A. (1997) Deregulated inflammatory response in mice lacking the STK/RON receptor tyrosine kinase. Genes Funct. 1: 69-83
13. D'Hellencourt, C. L., Diaw, L., Cornillet, P., Guenounou, M. (1996) Differential regulation of TNF-α, IL-1β, IL-6, IL-8, TNF-β, and IL-10 by pentoxifylline. Int. J. Immunopharmacol. 18: 739-748
14. Dal Piaz, V., Gioyannoni, M. P. (2000) Phosphodiesterase 4 inhibitors, structurally unrelated to rolipram, as promising agents for the treatment of asthma and other pathologies. Eur. J. Med. Chem. 35: 463-480
15. Dimmock, J. R., Sidhu, K. K., Quail, J. W., Jia, Z., Duffy, M. J., Reid, R. S., Kirkpatrick, D. L., Zhu, L., Fletcher, S. M. (1992) Synthesis and cytotoxic evaluation of some 6-arylidene-2 -(alpha-hydroxyamino-alpha-arylmethyl)cyclohexanone oximes and related compounds. J. Pharm. Sci. 81: 1059-1064
16. Ding, A., Nathan, C. F., Stuehr, D. J. (1988) Release of reactive nitrogen intermediates and reactive oxygen intermediates from mouse peritoneal macrophages. J. Immunol. 141: 2407-2418
17. Dinter, H., Tse, J., Halks-Miller, M., Asarnow, D., Onuffer, J., Faulds, D., Mitrovic, B., Kirsch, G., Laurent, H., Esperling, P., Seidelmann, D., Ottow, E., Schneider, H., Tuohy, V. K., Wachtel, H., Perez, H. D. (2000) The type IV phosphodiesterase specific inhibitor mesopram inhibits experimental autoimmune encephalomyelitis in rodents. J. Neuroimmunol. 108: 136-146
18. 3H]rolipram binding activity and their relationship to emetic behavior in the ferret. J. Med. Chem. 39: 120-125
19. Essayan, D. M. (1999) Cyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulation. Biochem. Pharmacol. 57: 965-973
20. Ferrara, N. (2000) Vascular endothelial growth factor and the regulation of angiogenesis. Recent Prog. Horm. Res. 55: 15-36
21. Francischi, J. N., Yokoro, C. M., Poole, S., Tafuri, W. L., Cunha, F. Q., Teixeira, M. M. (2000) Anti-inflammatory and analgesic effects of the phosphodiesterase 4 inhibitor rolipram in a rat model of arthritis. Eur. J. Pharmacol. 399: 243-249
22. Garrison, L., McDonnell, N. D. (1999) Etanercept: Therapeutic use in patients with rheumatoid arthritis. Ann. Rheum. Dis. 58 (Suppl. 1): 165-169
23. Geng, Y., Maier, R., Lotz, M. (1995) Tyrosine kinases are involved with the expression of inducible nitric oxide synthase in human articular chondrocytes. J. Cell Physiol. 163: 545-554
24. Harriman, G., Harper, L. K., Schaible, T. F. (1999) Summary of clinical trials in rheumatoid arthritis using infliximab, an anti-TNFalpha treatment. Ann. Rheum. Dis. 58 (Suppl. 1): I61-I164
25. Heaslip, R. J., Evans, D. Y. (1995) Emetic, central nervous system, and pulmonary activities of rolipram in the dog. Eur. J. Pharmacol. 286: 281-290
26. Jackson, J. R., Bolognese, B., Hillegass, L., Kassis, S., Adams, J., Griswold, D. E., Winkler, J. D. (1998) Pharmacological effects of SB 220025, a selective inhibitor of p38 mitogen-activated protein kinase, in angiogenesis and chronic inflammatory disease models. J. Pharmacol. Exp. Ther. 284: 687-692
27. Jimenez, J. L., Punzon, C., Navarro, J., Munoz-Ferandez, M. A., Fresno, M. (2001) Phosphodiesterase 4 inhibitors prevent cytokine secretion by T lymphocytes by inhibiting nuclear factor-kappaB and nuclear factor of activated T cells activation. J. Pharmacol. Exp. Ther. 299: 753-759
28. Lee, J. C., Laydon, J. T., McDonnell, P. C., Gallagher, T. F., Kumar, S., Green, G., McNulty, D., Blumenthal, M. J., Hets, J. R., Landvatter, S. W., Strickler, J. E., McLaughlin, M. M., Siemens, I. R., Fisher, S. M., Livi, G. P., White, J. R., Adams, J. L., Young, P. R. (1994) A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature 372: 739-746
29. Newton, R. C., Decicco, C. P. (1999) Therapeutic potential and strategies for inhibiting tumor necrosis factor-alpha. J. Med. Chein. 42: 2295-2314
30. Novogrodsky, A., Vanichkin, A., Patya, M., Gazit, A., Osherov, N., Levitzki, A. (1994) Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science 264: 1319-1322
31. Palfreyman, M. N. (1995) Phosphodiesterase type IV inhibitors as anti-inflammatory agents, Drugs Future 20: 793-804
32. Panayi, G. S., Lanchbury, J. S., Kingsley, G. H. (1992) The importance of the T-cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis. Arthritis Rheum. 35: 729-735
33. Park, J. S., Baik, K. U., Son, H. J., Cho, J. Y., Park, J., Lee, J. H., Lee, S. J., Yoo, E. S., Park, M. H. (2000a) The discovery of novel lead compound for the inhibition of tumor necrosis factor-α production. Korean J. Med. Chem. 10: 6-9
34. Park, J. S., Baik, K. U., Son, H. J., Lee, J. H., Lee, S. J., Cho, J. Y., Park, J., Yoo, E. S., Byun, Y. S., Park, M. H. (2000b) Synthesis and structure-activity relationships of novel compounds for the inhibition of TNF-α production. Arch. Pharm. Res. 23: 332-337
35. Park, J. S., Baik, K. U., Cho, J. Y., Yoo, E. S., Byun, Y. S., Park, M. H. (2001) Noble 2-[3-(cyclopentyloxy)-4-methoxyphenyl]-1-isoindolinone derivatives. part I: Synthesis and SAR studies for the inhibition of TNF-alpha production. Arch. Pharm. Res. 24: 367-370
36. Park, J. S., Moon, S. C., Baik, K. U., Cho, J. Y., Yoo, E. S., Byun, Y. S., Park, M. H., Balk, K. U. (2002) Synthesis and SAR studies for the inhibition of TNF-alpha production. Part 2. 2-[3-(Cyclopentyloxy)-4-methoxyphenyl]-substituted-1-isoindolinone derivatives. Arch. Pharm. Res. 25: 137-142
37. Qin, Z., Blankenstein, T. (1996) Influence of local cytokines on tumor metastasis: Using cytokine gene-transfected tumor cells as experimental models. Curr. Top. Microbiol Immunol. 213: 55-64
38. Renzetti, L. M., Paciorek, P. M., Tannu, S. A, Rinaldi, N. C., Tocker, J. E., Wasserman, M. A., Gater, P. R. (1996) Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways. J. Pharmacol. Exp. Ther. 278: 847-853
39. Sajjadi, F. G., Takabayashi, K., Foster, A. C., Domingo, R. C., Firestein, G. S. (1996) Inhibition of TNF-α expression by adenosine: Role of A3 Adenosine receptors. J. Immunol. 156: 3435-3442
40. Schmidt, D. T., Watson, N., Dent, G., Ruhlmann, E., Branscheid, D., Magnussen, H., Rabe, K. F. (2000) The effect of selective and non-selective phosphodiesterase inhibitors on allergen- and leukotriene C(4)-induced contractions in passively sensitized human airways. Br. J. Pharmacol. 131: 1607-1618
41. Schudt, C., Tenor, H., Hatzelmann, A. (1995) PDE isoenzymes as targets for anti-asthma drugs. Eur. Respir. J. 8: 1179-1183
42. Sekut, L., Connolly, K. M. (1996) Pathophysiology and regulation of TNF-α in inflammation. Drug News Perspect. 9: 261-269
43. Soderling, S. H., Beavo, J. A. (2000) Regulation of cAMP and cGMP signaling: New phosphodiesterases and new functions. Curr. Opin. Cell Biol. 12: 174-179
44. Weinstein, S. L., Sanghera, J. S., Lemke, K., DeFranco, A. L., Pelech, S. L. (1992) Bacterial lipopolysaccharide induces tyrosine phosphorylation and activation of mitogen-activated protein kinases in macrophages. J. Biol. Chem. 267: 14955-14962